Dropoetin 4000IU by Drogsan — Professional Erythropoietin for Clinical Anemia Management
Dropoetin 4000IU is a specialized glycoprotein cytokine indicated for the treatment of anemia associated with chronic renal failure. Designed for use in both pediatric and adult patients undergoing hemodialysis or peritoneal dialysis, this formulation supports clinical management in complex renal insufficiency cases. Whether used for managing anemia in cancer patients or facilitating autologous blood collection, Dropoint provides a reliable solution for healthcare professionals.
Specifications
| Manufacturer | Drogsan |
| Active Substance | Erythropoietin |
| Classification | Glycoprotein Cytokine |
| Form | 6 pre-filled Syringes |
Product Overview and Usage
Dropoetin is indicated for the treatment of anemia in patients with renal insufficiency and those receiving chemotherapy for non-myeloid malignancies. It is also utilized to reduce transfusion requirements in specific clinical settings, such as assisting in blood collection for pre-deposit programs. For patients with Myelodysplastic Syndrome (MDS) presenting with low or intermediate risk, Dropoetin serves as a vital tool in managing hemoglobin levels.
When administering this medication, healthcare providers must adhere to strict clinical protocols. The product should be handled with care; do not shake, freeze, or dilute the solution unless specifically directed by a medical professional. For home-use scenarios, providers must ensure the patient or caregiver is fully trained in the correct administration procedures to prevent contamination and ensure dosage accuracy.
Frequently Asked Questions
How should Dropoetin be administered?- Use only as directed by a healthcare professional.
- The product is typically administered in a hospital, clinic, or doctor's office.
- Always verify the dosage before administration.
- Do not use the product if it appears cloudy, discolored, or contains particles.
- Follow local rules for the disposal of needles and syringes.
- Serious reactions may include hypertension, seizures, or PRCA.
- There is a risk of increased mortality, myocardial infarction, stroke, and thromboembolism.
- In cancer patients, there is a potential for increased tumor progression or recurrence.
- Serious allergic reactions should be monitored closely.
- Do not use if the product has been frozen.
- Do not shake the solution.
- Keep out of reach of children and pets.
- Keep all syringes and needles out of reach of children.